Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20598874 | 0.92 | CSF1R (0.56) | CSF1RNTRK1SRPK1MEN1KMT2A | |
| SCHEMBL20598706 | 0.91 | CSF1R (0.64) | CSF1ROPRM1OPRD1MAPK1POLB | |
| SCHEMBL20598375 | 0.86 | SMN1; SMN2 (0.56) | CSF1ROPRM1OPRD1NTRK1SRPK1 | |
| SCHEMBL20598719 | 0.86 | CSF1R (0.55) | CSF1RNTRK1SRPK1MEN1KMT2A | |
| SCHEMBL20598851 | 0.84 | CSF1R (0.54) | CSF1RNTRK1GAAMEN1KMT2A | |
| SCHEMBL20598344 | 0.83 | CSF1R (0.55) | CSF1RNTRK1GAAMEN1KMT2A | |
| SCHEMBL20598529 | 0.83 | CSF1R (0.50) | CSF1ROPRM1OPRD1NTRK1SRPK1 | |
| SCHEMBL20598030 | 0.81 | CHEK1 (0.58) | CSF1RNTRK1KITAXLFLT3 | |
| SCHEMBL20598168 | 0.81 | IRAK4 (0.57) | CSF1RNTRK1KITAXLFLT3 | |
| SCHEMBL20598619 | 0.81 | CSF1R (0.51) | CSF1ROPRM1OPRD1NTRK1SRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | claimed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | claimed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | claimed |
| EP-3645525-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | Rigel Pharmaceuticals, Inc. (US) | 2020-05-06 | — | — | EP | claimed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | claimed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | claimed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3645525-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | Rigel Pharmaceuticals, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019006126-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002455-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CSF1R 693/4885OPRM1 4420/4885OPRD1 4446/4885 |
| US-20210309655-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CSF1R 693/4885OPRM1 4420/4885OPRD1 4446/4885 |
| US-10590121-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | CSF1R 419/4885OPRM1 4244/4885OPRD1 4258/4885 |
| US-20200181135-A1 | KINASE INHIBITORS AND METHODS FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | CSF1R 693/4885OPRM1 4420/4885OPRD1 4446/4885 |
| US-11059814-B2 | Kinase inhibitors and methods for making and using | IRAK1, IRAK2, IRAK3 | CSF1R 569/4885OPRM1 4259/4885OPRD1 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.